Breakdown | ||
Dec 2024 | Dec 2023 | Dec 2022 |
---|---|---|
Income Statement | Total Revenue | |
0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -1.28M | -250.00K | EBIT |
-300.75M | -158.17M | -113.85M | EBITDA |
-297.60M | -156.89M | -113.60M | Net Income Common Stockholders |
-294.23M | -154.99M | -111.93M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |
288.26M | 48.95M | 93.07M | Total Assets |
340.99M | 89.61M | 108.17M | Total Debt |
30.72M | 32.58M | 1.78M | Net Debt |
-138.80M | -13.42M | -24.04M | Total Liabilities |
80.89M | 53.50M | 17.94M | Stockholders Equity |
260.10M | 36.11M | 90.23M |
Cash Flow | Free Cash Flow | |
-256.81M | -134.47M | -110.13M | Operating Cash Flow |
-255.08M | -129.97M | -107.72M | Investing Cash Flow |
-113.79M | 60.47M | -68.75M | Financing Cash Flow |
492.37M | 89.68M | 101.63M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $62.69B | 14.96 | 15.95% | 0.15% | 8.27% | 10.35% | |
75 Outperform | $133.70B | 280.39 | 2.28% | 2.89% | 6.16% | -91.54% | |
75 Outperform | $158.15B | 38.94 | 67.55% | 3.10% | 18.64% | -39.39% | |
64 Neutral | $122.02B | ― | -3.15% | ― | 11.64% | -114.72% | |
48 Neutral | $9.69B | ― | -28.77% | ― | -52.75% | 25.00% | |
47 Neutral | $2.36B | -3.00 | -21.73% | 3.58% | 3.97% | -28.71% | |
43 Neutral | $546.79M | ― | -198.66% | ― | ― | -82.41% |
On March 4, 2025, Alumis Inc. and ACELYRIN, Inc. announced their commitment to merge in an all-stock transaction, forming a leading clinical-stage biopharma company focused on immune-mediated diseases. The merger is expected to enhance the combined company’s financial position, support a diverse pipeline, and drive significant value for stockholders. The transaction, anticipated to close in the second quarter of 2025, will provide increased resources for developing life-changing medicines and is projected to maximize value for shareholders and patients through a strengthened late-stage portfolio and financial flexibility.
On February 18, 2025, Alumis Inc. approved a Severance and Change in Control Plan to provide severance benefits and Change in Control benefits to eligible employees upon qualifying termination of employment. The plan details cash payments, COBRA premium payments, and potential acceleration of equity awards for eligible employees both during and outside Change in Control periods, depending on their designation tier.
On February 6, 2025, Alumis Inc. announced a merger agreement with ACELYRIN, Inc., creating a combined company dedicated to developing transformative therapies for immune-mediated diseases. The all-stock transaction, subject to stockholder approval, will see Alumis and ACELYRIN stockholders owning approximately 55% and 45% of the combined entity, respectively. The merger is expected to expand Alumis’ late-stage pipeline, including ACELYRIN’s lonigutamab, and provide financial stability with a pro forma cash position of $737 million. The combined company will operate under the Alumis name, led by the current Alumis executive team, and aims to leverage its R&D success and proprietary data platform to advance its differentiated portfolio. The transaction is anticipated to close in the second quarter of 2025, with stockholders representing substantial shares of both companies already in support.